Shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) saw an uptick in trading volume on Thursday . 1,201,723 shares traded hands during mid-day trading, a decline of 24% from the previous session’s volume of 1,586,014 shares.The stock last traded at $8.64 and had previously closed at $8.17.

Several brokerages recently issued reports on ACHN. JMP Securities raised Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $13.00 price target on the stock in a report on Thursday. Leerink Swann reissued a “hold” rating on shares of Achillion Pharmaceuticals in a report on Sunday, June 12th. Zacks Investment Research raised Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a report on Thursday, May 5th. Jefferies Group reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a research note on Thursday, May 5th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $10.00 target price on shares of Achillion Pharmaceuticals in a research note on Monday, June 6th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Achillion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $10.43.

The company has a 50 day moving average price of $8.78 and a 200-day moving average price of $8.11. The stock’s market cap is $1.21 billion.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. During the same period in the prior year, the business earned ($0.17) EPS. On average, analysts forecast that Achillion Pharmaceuticals Inc. will post ($0.65) earnings per share for the current fiscal year.

Several large investors recently added to or reduced their stakes in the stock. Marshall Wace LLP raised its stake in Achillion Pharmaceuticals by 36.8% in the fourth quarter. Marshall Wace LLP now owns 970,862 shares of the biopharmaceutical company’s stock valued at $10,476,000 after buying an additional 261,007 shares in the last quarter. Morgan Stanley raised its stake in Achillion Pharmaceuticals by 738.4% in the fourth quarter. Morgan Stanley now owns 233,221 shares of the biopharmaceutical company’s stock valued at $2,517,000 after buying an additional 205,405 shares in the last quarter. Rhumbline Advisers raised its stake in Achillion Pharmaceuticals by 14.0% in the fourth quarter. Rhumbline Advisers now owns 117,525 shares of the biopharmaceutical company’s stock valued at $1,268,000 after buying an additional 14,425 shares in the last quarter. ProShare Advisors LLC raised its stake in Achillion Pharmaceuticals by 10.1% in the fourth quarter. ProShare Advisors LLC now owns 126,923 shares of the biopharmaceutical company’s stock valued at $1,370,000 after buying an additional 11,681 shares in the last quarter. Finally, Swiss National Bank raised its stake in Achillion Pharmaceuticals by 6.8% in the fourth quarter. Swiss National Bank now owns 152,400 shares of the biopharmaceutical company’s stock valued at $1,644,000 after buying an additional 9,700 shares in the last quarter.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.